Pfizer Inc. (PFE)
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (April 2025)
Shares of Pfizer ( NYSE: PFE ) have been battered over the past month, falling by -16.44%, outpacing the market's loss of -9.44% over the same period.
Pfizer: Is The Dividend Yield Worth The Effort
Despite its historical underperformance and declining dividend growth trajectory, Pfizer's 7.63% dividend yield is attractive, making it a compelling income stock candidate. CEO Bourla's strategic focus on R&D, cost-cutting, and new revenue streams from acquisitions aims to mitigate upcoming revenue losses and drive future growth. Despite current challenges, Pfizer's robust cash flow, cost-saving initiatives, and potential new blockbusters by 2030 present a speculative but promising investment opportunity.
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?
Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has caught fire in recent years. The leading medicines in this field include household names such as Wegovy and Zepbound, two drugs whose sales are rapidly growing.
Pfizer (PFE) Laps the Stock Market: Here's Why
Pfizer (PFE) closed the most recent trading day at $22.15, moving +0.48% from the previous trading session.
Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield
Pfizer has faced headwinds post-COVID, but remains a key player with a robust R&D pipeline and an attractive 7.5%+ dividend yield. The pharmaceutical industry thrives on high R&D investment and patent protections, making Pfizer's development pipeline crucial for long-term growth. Despite recent setbacks, Pfizer's strategic initiatives, including cost-cutting and acquisitions, position it for future profitability and market leadership.
Pfizer: Tasty 7% Yield
Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. The biopharma has a robust pipeline with potential mega blockbuster cancer drugs and a reduced reliance on Covid-related sales. The company maintains robust cash flows, covering R&D and dividends, and recently sold $6 billion in Haleon shares, boosting liquidity.
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in weight-loss drugs may prompt it to consider acquiring VKTX, adding VK2735 and VK2809 to its pipeline. VK2735's dual administration routes and dual GLP-1/GIP agonist mechanism position it as a strong contender in the growing $37.94 billion anti-obesity market.
Pfizer Halts Obesity Pill Development Amid Safety Concerns
PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Bad news for Pfizer (PFE 1.07%) turned into good news for Eli Lilly (LLY 2.42%), Novo Nordisk (NVO 2.23%), and Viking Therapeutics (VKTX 8.48%) Monday morning, each of which is rising on Pfizer's latest product announcement.
Biotech Stock A Big Winner After Pfizer Halts Weight-Loss Drug
Viking Therapeutics Inc (NASDAQ:VKTX) stock is up 10.1% to trade at $24.42 today, and traded as high as $27.09 earlier in the session.
Pfizer Halts Development of Obesity Drug After Patient Sustains 'Liver Injury'
Pfizer (PFE) said it will stop development of an oral daily weight-loss pill after a participant taking the drug in a clinical trial experienced a liver injury.
Pfizer discontinues development of weight loss pill
Pfizer Inc (NYSE:PFE, ETR:PFE) announced it will discontinue the development of its experimental weight-loss pill, danuglipron, due to safety concerns. The company said on Monday that the decision comes after a clinical trial participant experienced a potential drug-induced liver injury, which resolved after stopping the medication.
